CompletedNCT03321526
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
This study evaluated the safety and effectiveness of JNJ-42847922 for people with depression.
Medication studyAges 18–70United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-42847922 for people with depression.
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Phoenix and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 12, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 107
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT03321526
- Official title
Show the full official title
A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Get this study by email
Recruitment & locations
CompletedPhoenix · Tempe · Rogers
41 more locations
- Garden Grove
- Los Angeles
- Oceanside
- Rancho Mirage
- Redlands
- San Diego
- Santa Ana
- Norwalk
- Coral Gables
- Kissimmee
- Miami
- New Port Richey
- Tampa
- Marietta
- Bolingbrook
- Crystal Lake
- Hoffman Estates
- Skokie
- Jeffersonville
- Iowa City
- Prairie Village
- Baltimore
- New Bedford
- Roslindale
- Rochester Hills
- Saint Charles
- St Louis
- Las Vegas
- Brooklyn
- Jamaica
- New York
- Raleigh
- Cincinnati
- Norman
- Oklahoma City
- Lincoln
- Arlington
- Houston
- Richardson
- Clinton
- Bellevue
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-42847922 for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitor (SNRI).
Who was this study for?
Listed age limits: 18 years to 70 years.
